Literature DB >> 33507360

Re: Results of a randomized trial of treatment modalities in patients with low or early‑intermediate risk prostate cancer (PREFERE trial).

Andreas Boehle1,2, Frank Kahmann3, Thomas Oliver Henkel3, Joerg Zimmermann4, Stefan Machtens5.   

Abstract

The authors of this "Letter to the Editors" express their major concern about selective and biased reporting in this paper.

Entities:  

Mesh：

Year:  2021        PMID： 33507360      PMCID： PMC7954738          DOI： 10.1007/s00432-020-03499-x

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.553


  1 in total

1.  Reply to Andreas Boehle, Frank Kahmann, Thomas Oliver Henkel, Joerg Zimmermann and Stefan Machten's to the Letter to the editor Re: results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial).

Authors:  Thomas Wiegel; Peter Albers; Detlef Bartkowiak; Roswitha Bussar-Maatz; Martin Härter; Glen Kristiansen; Peter Martus; Stefan Wellek; Heinz Schmidberger; Klaus Grozinger; Peter Renner; Fried Schneider; Martin Burmester; Michael Stöckle
Journal:  J Cancer Res Clin Oncol       Date:  2021-04       Impact factor: 4.553
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.